Nestlé Unit Invests Another $200M In Food Allergy Drug Co.
A Nestlé S.A. unit deepened its commitment to allergy-focused biopharmaceutical Aimmune Therapeutics with a $200 million equity investment to help bring its peanut allergy drug to market, the companies said Wednesday....To view the full article, register now.
Already a subscriber? Click here to view full article